Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 15 Sarcoma 4 Tumor-Agnostic 2 CNS 2 Thoracic 1 Plasma cell 1 Lymphoid 1

Conditions

Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 166 Rituximab 153 Specimen Handling 111 Biopsy 89 Magnetic Resonance Spectroscopy 87 Vincristine 85 Doxorubicin 79 Prednisone 78 fludarabine 68 venetoclax 65 obinutuzumab 60 ibrutinib 54 Lenalidomide 53 Dexamethasone 53 Cytarabine 47 Methotrexate 44 acalabrutinib 42 Etoposide 41 CT-P10 39 blinatumomab 38 Bendamustine Hydrochloride 34 fludarabine phosphate 33 prednylidene 32 Gemcitabine 32 deltacortene 31 Calcium Dobesilate 30 zanubrutinib 29 pembrolizumab 29 glofitamab 27 Nivolumab 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

regorafenib × Lymphoid × 90 days × Clear all

NCT02693535 2026-05-29

TAPUR

American Society of Clinical Oncology

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡